title: Methyl-methoxylpyrrolinone and flavinium nucleus binding signatures on falcipain-2 active site.
abstract: Following the increasing reports of human toxicity and plasmodium resistance to artemisinin and its derivatives, falcipain-2 (FP-2) is now emerging as the choice antimalarial drug target. Coincidentally, FP-2 is the in vivo target of naturally occurring, therapeutically safe flavonoids (stenopalustroside, myricetin, and fisetin) and symplostatin (symplostatin 4) compounds known to exhibit potent in vitro and in vivo antiplasmodial actions. Here, the structural bases for their inhibitory actions have been studied using molecular dynamics simulation. Myricetin and fisetin act as proton transfer tunnel breakers by inserting between His174 and Cys42, which are key active site residues of FP-2, stenopalustroside inhibits the polarization of His174 by Asn173; a major preparatory step for Cys42/His174 proton transfer process. The roles of flavonoids are favored by T-shaped pi-pi interactions with His174. Symplostatin 4 inserts its methyl-methoxylpyrrolinone moiety into the active site where its proton acceptor function prepares Cys42 for nucleophilic attack on the Michael α,β-unsaturated bonds on its 4(S)-amino-2(E)-pentenoate moiety. Further analyses of the structures identified a unique bridge formed on FP-2 active site groove by stenopalustroside and symplostatin 4 during interaction with the sub-site I of FP-2, whereas fisetin preferentially interacts with sub-site II and myricetin interacts with sub-site III residues. Ultimately, symplostatin-4, myricetin, and fisetin were better than stenopalustroside at trapping FP-2 in its inactive state as revealed by comparative RSMD plots with X-ray structures of FP-2 co-crystallized with inhibitors. Comparative estimates of free energy of binding using the Molecular Mechanics-Poisson Boltzmann Surface Area (MMPBSA) method suggested that His174 protonation may further enhance stenopalustroside-FP-2 interaction. The unique binding signatures of the ligands within the FP-2 active site groove and its sub-sites may explain the subtle differences in their IC50 values and their mechanism of inhibition.
authors.affiliation: Center for Drug Discovery and Therapeutic Innovation, Nagasaki University, Nagasaki, Japan, bbis11r104@cc.nagasaki-u.ac.jp.
authors.forename: Olaposi I
authors.initials: OI
authors.lastname: Omotuyi
mesh_terms: D023181:Antimicrobial Cationic Peptides; D020134:Catalytic Domain; D003546:Cysteine Endopeptidases / Q000737:chemistry* / Q000378:metabolism*; D005415:Flavins / Q000737:chemistry / Q000378:metabolism*; D005419:Flavonoids / Q000737:chemistry / Q000494:pharmacology; D044948:Flavonols; D008024:Ligands; D056004:Molecular Dynamics Simulation; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D011480:Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology; D011522:Protons; D011758:Pyrroles / Q000737:chemistry / Q000378:metabolism*; D013816:Thermodynamics
chemical_list: D023181:Antimicrobial Cationic Peptides; D005415:Flavins; D005419:Flavonoids; D044948:Flavonols; D008024:Ligands; D010455:Peptides; D011480:Protease Inhibitors; D011522:Protons; D011758:Pyrroles; C534687:gallinamide A; C013231:pyrroline; C040015:myricetin; D003546:Cysteine Endopeptidases; C416224:falcipain 2; C017875:fisetin
references.citation: J Pharm Pharmacol. 2009 Nov;61(11):1401-33
references.pmid: 19903367
references.citation: Int J Parasitol Drugs Drug Resist. 2013 Jun 28;3:119-28
references.pmid: 24533301
references.citation: Chemistry. 2006 May 3;12(14):3821-8
references.pmid: 16514687
references.citation: Expert Rev Anti Infect Ther. 2009 Nov;7(9):1087-98
references.pmid: 19883329
references.citation: Am J Clin Nutr. 2001 Oct;74(4):418-25
references.pmid: 11566638
references.citation: Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5392-7
references.pmid: 23471987
references.citation: Biochim Biophys Acta. 2000 May 12;1458(1):6-27
references.pmid: 10812022
references.citation: Fitoterapia. 2014 Apr;94:55-61
references.pmid: 24468190
references.citation: J Biol Chem. 2006 Sep 1;281(35):25425-37
references.pmid: 16777845
references.citation: Crit Rev Toxicol. 2010 May;40(5):405-21
references.pmid: 20158370
references.citation: PLoS One. 2012;7(10):e47227
references.pmid: 23077573
references.citation: J Comput Chem. 2005 Dec;26(16):1701-18
references.pmid: 16211538
references.citation: Lancet. 2004 Jan 3;363(9402):9-17
references.pmid: 14723987
references.citation: Chem Res Toxicol. 2003 Apr;16(4):512-23
references.pmid: 12703968
references.citation: Curr Top Med Chem. 2012;12(5):408-44
references.pmid: 22242849
references.citation: Structure. 2011 Jul 13;19(7):919-29
references.pmid: 21742259
references.citation: Blood Cells Mol Dis. 2005 Sep-Oct;35(2):201-11
references.pmid: 16087367
references.citation: J Chem Inf Model. 2012 Mar 26;52(3):696-710
references.pmid: 22332946
references.citation: Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):E653-61
references.pmid: 23382230
references.citation: Chemistry. 2011 Nov 25;17(48):13544-52
references.pmid: 22006835
references.citation: N Engl J Med. 2008 Dec 11;359(24):2619-20
references.pmid: 19064625
references.citation: BMC Res Notes. 2008 Jun 18;1:26
references.pmid: 18710482
references.citation: PLoS One. 2013;8(3):e57689
references.pmid: 23520478
references.citation: Chem Biol. 2012 Dec 21;19(12):1546-55
references.pmid: 23261598
references.citation: J Med Chem. 2005 May 19;48(10):3654-8
references.pmid: 15887974
references.citation: Future Med Chem. 2012 Dec;4(18):2295-310
references.pmid: 23234552
references.citation: J Biomol Struct Dyn. 2015;33(5):1027-36
references.pmid: 24943200
references.citation: J Nat Prod. 2009 Jan;72(1):14-7
references.pmid: 19161344
references.citation: Nature. 2014 Jan 2;505(7481):50-5
references.pmid: 24352242
references.citation: Mol Phys. 2009;107(4-6):423-431
references.pmid: 19920881
references.citation: PLoS Pathog. 2008 Apr 25;4(4):e1000053
references.pmid: 18437218
references.citation: Front Chem. 2013 Dec 27;1:39
references.pmid: 24790966
references.citation: Pediatr Res. 2009 May;65(5 Pt 2):64R-70R
references.pmid: 19918214
references.citation: J Med Chem. 2009 Feb 12;52(3):852-7
references.pmid: 19128015
references.citation: Org Lett. 2010 Dec 3;12(23):5576-9
references.pmid: 21049908
references.citation: Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9138-43
references.pmid: 15964982
references.citation: Med Res Rev. 2010 Jan;30(1):136-67
references.pmid: 19526594
references.citation: Lancet Infect Dis. 2004 Jun;4(6):327-36
references.pmid: 15172341
references.citation: Structure. 1999 Mar 15;7(3):R55-60
references.pmid: 10368306
references.citation: Biophys J. 2003 Jul;85(1):159-66
references.pmid: 12829472
references.citation: J Chem Inf Model. 2011 Apr 25;51(4):852-64
references.pmid: 21428453
references.citation: J Chem Inf Model. 2014 Jul 28;54(7):1951-62
references.pmid: 24850022
references.citation: Proteins. 2012 Jan;80(1):93-110
references.pmid: 21971880
references.citation: PLoS One. 2009 May 27;4(5):e5694
references.pmid: 19479029
references.citation: Mol Interv. 2010 Feb;10(1):39-50
references.pmid: 20124562
references.citation: J Phys Chem A. 2006 Sep 21;110(37):10656-68
references.pmid: 16970354
references.citation: PLoS Med. 2006 Dec;3(12):e528
references.pmid: 17194200
references.citation: Structure. 2007 May;15(5):535-43
references.pmid: 17502099
references.citation: J Econ Entomol. 2012 Feb;105(1):85-91
references.pmid: 22420259